Czech J, Hoffmann D, Naik R, Sedlacek H
HOECHST INDIA LTD, BOMBAY, MAHARASHTRA, INDIA.
Int J Oncol. 1995 Jan;6(1):31-6.
L 86-8275, a flavone of novel structure, was shown to be a kinase inhibitor and to possess surprising potent antiproliferative potency (IC50=0.1-0.15 mu M) on various tumor cell lines after long period of incubation. Short period of incubation was significantly less effective (IC50=133 mu M). In vitro L 86-8275 showed almost no cross-resistance on L 1210 mouse leukemia tumor cell line 110-fold resistant to doxorubicin. In vivo significant antitumoral effects were seen with xenografted lung, colon, mammary and ovarian tumors as well as glioblastoma. T/C values ranged from 29 to 86% and were comparable to standard chemotherapeutic treatment. Optimal schedule required daily oral application of L 86-8275.
L 86-8275是一种结构新颖的黄酮,经证实是一种激酶抑制剂,在长时间孵育后,对多种肿瘤细胞系具有惊人的强效抗增殖能力(IC50 = 0.1 - 0.15 μM)。短时间孵育的效果则显著较差(IC50 = 133 μM)。在体外,L 86-8275对多柔比星耐药110倍的L 1210小鼠白血病肿瘤细胞系几乎没有交叉耐药性。在体内,L 86-8275对异种移植的肺癌、结肠癌、乳腺癌、卵巢癌以及胶质母细胞瘤均显示出显著的抗肿瘤作用。T/C值范围为29%至86%,与标准化疗治疗效果相当。最佳给药方案是每日口服L 86-8275。